Company: Abbott Laboratories
Ticker: ABT
Form: 10-K
Filed: 2026-02-20
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Abbott Laboratories's net income in fiscal year 2025?
Question Type: value_lookup

Concept: NetIncomeLoss
Answer (Numeric): 6524.0
Answer (Display): $6,524 million
Unit: USD millions

Evidence:
[{"chunk_id": "115", "equivalent_chunk_ids": ["115"], "section": "Consolidated Statement of Comprehensive Income", "supports": ["main"], "text": "(in millions)\nYear Ended December 31\nNet Earnings\n6,524\n13,402\n5,723\nForeign currency translation gain (loss) adjustments, net of taxes of $\nin 2025 and $\nin 2024 and 2023\n1,574\n1,001\nNet actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $\nin 2025, $\nin 2024, and $\nin 2023\nNet gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $(\n) in 2025, $\nin 2024, and $(\n) in 2023\nOther Comprehensive Income (Loss)\n1,905\nComprehensive Income\n8,429\n13,335\n5,935\nSupplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31:\nCumulative foreign currency translation (loss) adjustments\n5,931\n7,505\n6,504\nNet actuarial (losses) and prior service (cost) and credits\n1,376\nCumulative gains (losses) on derivative instruments designated as cash flow hedges\nAccumulated other comprehensive income (loss)\n6,001\n7,906\n7,839\nThe accompanying notes to consolidated financial statements are an integral part of this statement.\nAbbott Laboratories and Subsidiaries"}]

Derivation: